A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons

Biomedical Chromatography

Volumn 24, Issue 7, 2010, Pages 717-726

  Ren, Chen ^a   Fan Havard, Patty ^a,b   Schlabritz Loutsevitch, Natalia ^c   Ling, Yonghua ^a   Chan, Kenneth K ^a   Liu, Zhongfa ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Metabolites; Nevirapine; Pharmacokinetics; Quantification

Indexed keywords

BIOMOLECULES; BODY FLUIDS; ISOMERS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; QUALITY CONTROL;

DOSE-ESCALATION STUDY; LC-MS-MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LOWER LIMITS; NEVIRAPINE; ORAL DOSE; PHARMACOKINETIC STUDIES; QUANTIFI CATIONS; QUANTIFICATION;

METABOLITES;

12 HYDROXYL NEVIRAPINE; 2 HYDROXYL NEVIRAPINE; 3 HYDROXYL NEVIRAPINE; 4 CARBOXYL NEVIRAPINE; 8 HYDROXYL NEVIRAPINE; DRUG METABOLITE; NEVIRAPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FEMALE; LIQUID CHROMATOGRAPHY; NONHUMAN; QUALITY CONTROL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

PAPIO;

EID: 77952369572     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1353     Document Type: Article

References (26)

1. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Lion SH, Timpone J, Myers M, Basgoz N, Niu M and Hirsch MS. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infections Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Annals of Internal Medicine, 1996; 124: 1019-1030.
2. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F and Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
3. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C and Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18: 2391-2400.
4. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH and McNamara J. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. Journal of Acquired Immune Defi ciciency Syndrome 2004; 36: 772-776.
5. Hollanders RM, van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP and Hekster YA. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Biomedical Science Applications 2000; 744: 65-71.
6. Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF and Fan-Havard P. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstetrics and Gynecology 2005; 106: 1032-1038. (Pubitemid 41532910)
7. Knudtson E, Para M, Boswell H and Fan-Havard P. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodefi ciency virus. Obstetrics and Gynecology 2003; 101: 1094-1097. (Pubitemid 36566389)
8. Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M and Robinson P. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharmacy and Drug Disposition 1999; 20: 285-291. (Pubitemid 30071750)
9. Liu Z, Fan-Havard P, Xie Z, Ren C and Chan KK. A liquid chromatography/ atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons. Rapid Communications in Mass Spectrometry 2007; 21: 2734-2742. (Pubitemid 47255487)
10. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411-1413.
11. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M and Lange JM. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovusine for HIV-infected patients: the INCAS trial. Italy, the Netherlands, Canada and Australia study. The Journal of the American Medical Association 1998; 279: 930-937.
12. Murphy RL and Montaner J. Nevirapine: a review of its development, pharmacological profi le and potential for clinical use. Expert Opinions in Investigative Drugs 1996; 5: 1183-1199. (Pubitemid 26302639)
13. Olofson RA VMR. Mechanisms of the reactions of benzoazetinones with nucleophiles: evidence for an imino ketene intermediate. Journal of Organic Chemistry 1984; 49: 3377-3379.
14. Olofson RA VMR, Hoskin DH, Bernheim MY, Stournas S, Morrison DS. Synthesis, stability, structure, reactivity, and chemistry of N-alkylbenzoazentinones. Journal of Organic Chemistry 1984; 49: 3367-3372.
15. Pav JW, Rowland LS and Korpalski DJ HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis 1999; 20: 91-98.
16. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E and Masur H. Cytochrome P450 2B6 (CYP2B6) G516T infl uences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Medicine 2007; 8: 86-91. (Pubitemid 46390844)
17. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP and Merluzzi VJ. BI-RG-587 is active against zidovudine-resistant human immunodefi ciency virus type 1 and synergistic with zidovudine. Antimicrobial Agents and Chemotherapy 1991; 35: 305-308.
18. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J and Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metabolim and Disposition 1999a; 27: 895-901. (Pubitemid 29347589)
19. Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ and Hattox SE. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metabolim and Disposition 1999b; 27: 1434-1447.
20. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L and Telenti A. Infl uence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics 2005; 15: 1-5.
21. Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB and Morris JP. Quantitation of fi ve nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technology in Biomedicine and Life Science 2007; 856: 252-260.
22. Silverthorn CF and Parsons TL. A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography. Biomedical Chromatography 2006; 20: 23-27. (Pubitemid 43141401)
23. Smyth WF, McClean S and Ramachandran VN. A study of the electrospray ionisation of pharmacologically signifi cant 1,4-benzodiazepines and their subsequent fragmentation using an ion-trap mass spectrometer. Rapid Communications in Mass Spectrometry 2000; 14: 2061-2069.
24. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS and Mayers DL. A comprehensive hepatic safety analysis of nevirapine in diff erent populations of HIV infected patients. Journal of Acquired Immune Deficiency Syndrome 2003; 34(suppl. 1): S21-33.
25. van Heeswijk RP, Hoetelmans RM, Meenhorst PL, Mulder JW and Beijnen JH. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Biomedical Science Applications 1998; 713: 395-399.
26. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegvi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP and Lange JM. A randomized trail to study fi rst-line combination therapy with or without a protease inhibitor in HIV-1- infected patients. Aids 2003; 17: 987-999.